Implementation of Systemic Hedgehog Inhibitors in Daily Practice as Neoadjuvant Therapy
Autor: | Nikki Tang, Desiree Ratner |
---|---|
Rok vydání: | 2017 |
Předmět: |
Oncology
medicine.medical_specialty Pyridines medicine.medical_treatment Vismodegib Antineoplastic Agents Pharmacology Sonidegib 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Combined Modality Therapy Anilides Hedgehog Proteins Basal cell carcinoma Molecular Targeted Therapy Neoplasm Metastasis Hedgehog Neoadjuvant therapy Neoplasm Staging business.industry Biphenyl Compounds Standard of Care medicine.disease Neoadjuvant Therapy Biphenyl compound Radiation therapy Treatment Outcome chemistry Drug Resistance Neoplasm 030220 oncology & carcinogenesis business Signal Transduction medicine.drug |
Zdroj: | Journal of the National Comprehensive Cancer Network. 15:537-543 |
ISSN: | 1540-1413 1540-1405 |
DOI: | 10.6004/jnccn.2017.0051 |
Popis: | The most common cancer in both men and women is basal cell carcinoma (BCC). Although most primary and recurrent BCCs have high cure rates with standard therapies, advanced BCCs present a greater treatment challenge, especially in cosmetically and functionally sensitive areas. In patients unable to undergo surgery or radiation therapy, hedgehog inhibitors can be used neoadjuvantly to reduce tumor size, decreasing the extent and complexity of any subsequent surgery and providing either a cure or palliation. The goal of this review is to summarize the pharmacology, efficacy, and safety of systemic hedgehog inhibitors, as well as their role in daily practice as neoadjuvant therapy. Relevant English-language literature was identified and evaluated based on results from database searches of PubMed. Terms searched included, but were not limited to, "vismodegib," "Erivedge," "sonidegib," "DE225," "BCC," and "neoadjuvant treatment." Additional literature was identified from the reference lists of previously identified articles. The authors' personal experience in treating advanced BCC using hedgehog inhibitors has been incorporated into the recommendations made herein. |
Databáze: | OpenAIRE |
Externí odkaz: |